Genetic Counseling |
Family Medical History |
[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]
Clinical Trial: Evaluation of DBT - 1
This study is currently recruiting patients.
Purpose
| Condition | Intervention |
|---|---|
| Dialectical Behavior Therapy Drug Counseling Opioid Dependence | Behavior: Behavior Therapy |
MedlinePlus related topics: Drug Abuse
Study Type: Interventional
Study Design: Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Efficacy Study
Official Title: Evaluation of Dialectical Behavior Therapy (DBT)
Secondary Outcomes: Suicidal Behavior; Depression, anxiety, Axis I diagnostic remission
Expected Total Enrollment: 86
Study start: June 2004
Eligibility
Inclusion Criteria:
-1. Meets SCID-I criteria for opiate dependence.
2. Meets IPDE and SCID criteria for BPD (DSM-IV)
3. Over 18 years old
4. Resides within commuting distance of treatment
5. Consents to outpatient treatment for drug addiction
Exclusion Criteria:
-1. Bipolar, Schizophrenia, Schizophreniform, or Schizoaffective Disorders, Psychosis NOS
2. IQ less than 70; life threatening anorexia; current and chronic absence of shelter; impending jail/prison for more than three weeks (problems which by their presence or severity preclude ability to attend or understand treatment and/or requires priority treatment over SUD treatment)
3. Court order to treatment, court order to treatment or to jail, or agency order to treatment or loss of child custody (due to consequent inability to freely drop-out of treatment)
4. Is pregnant, plans to become pregnant during treatment phase, or becomes pregnant before random assignment to study condition
5. Is unable to tolerate suboxone induction phase
6. Is currently stable on methadone
7. Current benzodiazapine use from which the participant is unwilling to taper
8. Refuses: to discontinue current mental health or drug abuse treatment or random assignment.
Location and Contact Information
Washington
Behavioral Research and Therapy Clinics, Seattle, Washington, 98195 1525, United States; Recruiting
Marsha Linehan, Ph.D., Principal Investigator, University of Washington
More Information
Record last reviewed: June 2005
Last Updated: July 18, 2005
Record first received: July 7, 2005
ClinicalTrials.gov Identifier: NCT00117741
Health Authority: Federal Government
ClinicalTrials.gov processed this record on 2005-07-26
Resources
- Cancer Genetics Services Directory (National Cancer Institute)
- Career in Genetic Counseling (National Society of Genetic Counselors)

Not Signed In -


